Thiamine tetrahydrofurfuryl disulfide promotes voluntary activity through dopaminergic activation in the medial prefrontal cortex
SCIENTIFIC RepoRTS |
Thiamine tetrahydrofurfuryl disulfide promotes voluntary activity through dopaminergic activation in the medial prefrontal cortex
A physically active lifestyle is associated with better health in body and mind, and it is urgent that supporting agents for such lifestyles be developed. In rodents, voluntary locomotor activity as an active physical behavior may be mediated by dopaminergic neurons (DNs). Thiamine phosphate esters can stimulate DNs, and we thus hypothesized that thiamine tetrahydrofurfuryl disulfide (TTFD), a thiamine derivative, promotes locomotor activity via DNs in rats. Acute i.p. administration of TTFD enhanced rat locomotor activity in a normal cage. In vivo microdialysis revealed that TTFD-enhanced locomotor activity was synchronized with dopamine release in the medial prefrontal cortex (mPFC). Antagonism of the dopamine D1 receptor, but not D2 receptor, in the mPFC fully suppressed TTFD-enhanced locomotor activity. Finally, we found a TTFD dose-dependent increase in voluntary wheel running. Our findings demonstrate that DNs in the mPFC mediates TTFD-enhanced locomotor activity, suggesting the potential of TTFD to induce active physical behavior.
The higher the level of physical activity, the higher the levels of physical fitness. Higher levels of physical activity
produce various physiological and psychological benefits1,2, while inactivity leads to a lack of vitality in the body
and mind, making it a risk factor for lifestyle diseases, depression, and Alzheimer desease3?5. Globally, however,
23% of adults and 81% of adolescents do not meet the WHO Global Recommendations on Physical Activity for
Health6, and over 50% of employed adults and over 80% of over weight adults do not have leisure-time physical
activity7,8. Thus, measures to enhance motivation for physical activity are required in modern human society.
Motivated behaviors, including locomotion, feeding, glucose seeking, and learning and memory, are
regulated by the dopaminergic neurons (DNs)9?13. The substantia nigra pars compacta (SNc) and ventral tegmental
area (VTA) in the midbrain are the origin nucleus of DNs14, and, in particular, DNs from the VTA that project
into the medial prefrontal cortex (mPFC) are involved in the reward system15. Amphetamine (AMPH) injection
induces dose-dependent dopamine release in the mPFC and increases voluntary locomotor activity through the
dopamine D1 receptor in rats16?18. These data suggest that DNs in the mPFC are a potential target of agents that
induce motivation for physical activity.
Although we must be careful of addiction induced by drugs such as AMPH19, thiamine tetrahydrofurfuryl
disulfide (TTFD), a popular thiamine derivative, is a potential agent for the activation of DNs without severe side
effects. Thiamine deficiency causes the development of Wernicke?s encephalopathy20, hence thiamine plays an
important role in the central nervous system. TTFD is more rapidly absorbed than thiamine and it is metabolized
into thiamine and its phosphorylated esters, which are thiamine monophosphate (TMP), thiamine diphosphate
(TDP), and thiamine triphosphate (TTP)21,22. Chronic administration of TTFD ameliorates exercise-induced
fatigue likely through the effect of TDP as a coenzyme of pyruvate dehydrogenase of skeletal muscles in humans
and rats23,24. Further, the local injection of TTP and TDP into the rat striatum increases dopamine release25,
suggesting a possible role of TTFD on DNs in the brain. However, the effects of TTFD on the brain, particularly on
the DNs in the mPFC, and voluntary locomotor activity remain unclear.
A recent study showed that benfotiamine (BFT), another thiamine derivative, decreases stress-induced anxiety
behavior and GSK-3? activity in the PFC26. BFT also prevents stress-suppressed adult hippocampal neurogenesis
in predator-stressed mice, independent of brain TDP levels27,28, suggesting the potential of thiamine derivatives as
a psychopharmacological agents. TTFD has a similar bioavailability to BFT29, indicating the possibility for a role
of TTFD in the brain. Therefore, we hypothesized that TTFD has important effects on the brain and contributes
to the induction of physical activity via D1-receptor-mediated dopaminergic activity in the mPFC.
To test the present hypothesis, we employed a rat model of acute TTFD injection, voluntary locomotor
activity detection with infrared radiation, and in vivo microdialysis. First, we investigated the effect of acute TTFD
i.p. injection on voluntary activity in rats in a normal cage. Next, in vivo microdialysis revealed the dopamine
dynamics in the mPFC with TTFD injection. Third, we examined the inhibitory effects of dopamine D1 and D2
receptors on voluntary activity after TTFD injection. Finally, we assessed the effect of acute TTFD i.p. injection
on voluntary running distance in a wheel cage.
TTFD biphasically increases voluntary locomotor activity. Rats were given i.p. injection of TTFD
(50 mg/kg) or saline, and their voluntary activity in a normal cage were monitored for 90 min. TTFD increased
the total voluntary activity for the entire 90 min (P < 0.01, Fig.?1A), and we found a biphasic enhancement of
TTFD-induced voluntary activity at 10 to 20 min and 50 to 90 min after administration (P < 0.01, Fig.?1B). These
results are the first evidence for TTFD as a potential agent for inducing voluntary locomotor activity.
TTFD induces biphasic voluntary activity and dopamine release in the mPFC. Rats were given an
i.p. injection of TTFD (50 mg/kg) or saline, and the extracellular dopamine and serotonin levels in their mPFC
were measured using in vivo microdialysis for 120 min while monitoring voluntary activity in a normal cage
(Fig.?2A). Consistent with the first experiment, TTFD increased overall voluntary activity during the 120 min
monitored (P < 0.01, Fig.?2B), and a biphasic enhancement of TTFD-induced voluntary activity was observed at
10 to 20 min and 60 to 80 min after administration (P < 0.01, Fig.?2C). Extracellular dopamine levels in the mPFC
also increased biphasically at 20 to 40 min and 60 to 120 min after administration (P < 0.05, Fig.?2D). Serotonin
levels remained basically unchanged but increased at 70 min after administration (P < 0.05, Fig.?2E). These results
indicate the possibility that TTFD-enhanced voluntary activity is due to dopaminergic activation in the mPFC.
Antagonism of the dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppresses
TTFD-induced voluntary activity. To examine whether TTFD induces voluntary activity through
dopaminergic activation in the mPFC, we injected antagonists of the dopamine D1 and D2 receptors into the rat
mPFC using microdialysis 30 min after TTFD administration. TTFD increased the total voluntary locomotor
activity (P < 0.01), but the D1 receptor antagonist (SCH23390) fully inhibited the second peak of TTFD-induced
voluntary activity (Fig.?3A). A D2 receptor antagonist (sulpiride) increased activity after injection (Fig.?3A,B),
which is consistent with previous studies using D2-receptor antagonists30,31. In the present experiment, both
antagonists increased dopamine and serotonin release in the mPFC (Fig.?S1), indicating the validity of
antagonist injection for central dopamine receptors32. We also injected SCH23390 into the mPFC 20 min before TTFD
administration, and found that the antagonism of the D1 receptor fully inhibited both peaks of TTFD-induced
voluntary locomotor activity (P < 0.01, Fig.?4A,B). These results directly support the present hypothesis that
TTFD contributes to the induction of voluntary locomotor activity via D1-receptor-mediated dopaminergic
activity in the mPFC.
TTFD dose-dependent increases in voluntary running distance in running-wheel cage. Finally,
we examined whether acute TTFD administration increases not only voluntary locomotor activity but also the
amount of running exercise using a running-wheel cage. The i.p. administration of TTFD increased voluntary
running distance in a dose-dependent manner (P < 0.05, Fig.?5A), particularly at 40 to 50 min after
administration (P < 0.01, Fig.?5B). These results imply that TTFD enhances not only voluntary locomotor activity but also
running exercise distance.
This study tested the hypothesis that TTFD contributes to the induction of voluntary activity via
D1-receptor-mediated dopaminergic activity in the mPFC. Our rat model of acute TTFD injection, voluntary
activity detection with infrared radiation, and in vivo microdialysis showed that TTFD biphasically increases both
voluntary activity and dopamine release in the mPFC (Figs?1 and 2). We also confirmed that antagonism of the
dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppresses TTFD-induced voluntary activity
(Figs?3 and 4). Furthermore, TTFD increased voluntary running distance in a dose-dependent manner in a wheel
cage (Fig.?5). These findings support the present hypothesis and provide evidence for a possible role of TTFD in
inducing physical activity.
Here, we determined the dose of the TTFD injection (50 mg/kg) based on a previous study that
examined how TTFD counters physical fatigue by improving energy metabolism during a swimming exercise23.
Previous studies investigating the effects of BFT on the brain employed 200 mg/kg26,28, which is four-fold higher
than the dose of TTFD in the present study. However, we observed that a dose of 50 mg/kg of TTFD induces
D1-receptor-mediated dopaminergic activity in the mPFC as well as voluntary activity (Figs?1?4). We also
confirmed that TTFD-induced voluntary running occurred with a dose of 50 mg/kg, but not with lower doses
(Fig.?5). These data suggest the validity of our TTFD injection model and that 50mg/kg is likely the lower dose
limit for observable effects of thiamine derivatives on rat brains.
TTFD induced biphasic voluntary locomotor activity at 10 to 20 min and 50 to 90 min after administration,
which was synchronized with dopaminergic activity via the D1 receptor, but not with serotonin release, in the
mPFC (Figs?1?4). This periodicity is consistent with the timing of the REM-nonREM sleep cycle in rats, which
is about 10 min (7?13 min)33. Here we performed experiments during the light period, when rats normally sleep.
Further, dopamine, rather than serotonin, plays an important role in the maintenance of an awake state via the
D1 receptor34,35. Therefore, a periodicity of at least two or more occurrences of TTFD-induced voluntary activity
might be due to an awake state regulated by dopaminergic activity in the REM-nonREM sleep cycle. However,
why first peak is sharp and second peak is long-lasting must be investigated in the further research.
Our in vivo microdialysis revealed TTFD-induced dopamine release in the mPFC (Fig.?2D). DNs from the
VTA (A10) project into the mPFC14, indicating that TTFD might activate DNs from the VTA. However, how
TTFD activates DNs is still unclear. A possible mechanism is the effect of TTFD-derived TDP, a coenzyme of
pyruvate dehydrogenase. Acetyl-CoA synthesized from pyruvate by pyruvate dehydrogenase is an important
neuronal energy source derived from glucose or lactate, and can contribute to neuronal firing36. Furthermore, a
previous study showed that local injection of TTP into the striatum increases dopamine release in the striatum, and
that this was disrupted by an Na+ channel blocker (TTX), but not by a Ca2+ channel blocker (?-CgTX)25. TTX
can prevent the Na+ flux caused by TTP37. These previous studies indicate the possibility that TTFD increases
dopamine release in the mPFC through energetic and signaling roles in enhancing Na+ permeability.
Furthermore, antagonism of the dopamine D1 receptor, but not the D2 receptor, in the mPFC fully suppressed
the TTFD-induced voluntary locomotor activity (Figs?3 and 4). These results are consistent with previous studies
showing that amphetamine increases dopamine release in the mPFC and locomotor activity of rats16,17, but that
amphetamine-induced locomotor activity is inhibited by antagonism of the D1 receptor in the mPFC18. Also, we
confirmed that antagonism of the D2 receptor induces a much higher level of locomotor activity (Fig.?3), which
is consistent with previous studies showing hyper-behavior induced by D2-receptor antagonists through a
disinhibiting effect30,31. Thus, we show the data with a D2-antagonist as a positive control, but this was excluded from
statistical analyses because this was a planned comparison38. These findings support the present hypothesis that
TTFD contributes to the induction of physical activity via D1-receptor-mediated dopaminergic activity in the
mPFC, providing evidence for a possible role of TTFD in inducing physical activity.
We also observed that TTFD induces not only locomotor activity in rats in a normal cage (Figs?1?4), but
also voluntary running in a dose-dependent manner in a running wheel cage at the timing following locomotor
activation (Fig.?5). The degree of voluntary running behavior is regulated by DNs, likely via the D1 receptor
in rodents31,39,40, suggesting a possible common neural mechanism in TTFD-induced locomotor activity and
voluntary running. Although the linkage between TTFD-induced locomotor activity and wheel running is not
fully investigated, TTFD-activated DNs together with locomotion could be a possible trigger for wheel running.
Furthermore, chronic exercise, which is mimicked in rodents by voluntary running in a wheel cage41,42, produces
various physiological and psychological benefits to prevent lifestyle diseases and to enhance brain functions in
rodents and humans43?46. Although how TTFD-induced voluntary exercise affects physical and mental functions
remains untested, TTFD may be a way to enhance active physical behavior with exercise and/or sport.
In general, motivation is the basis of animals? behaviors such as food seeking, sexual behavior, and drug
addiction relating with rewarding system47, which is regulated mainly by dopaminergic mechanisms48,49, and
locomotion is a tool of it. However, previous studies showed that exercise itself activates dopamine metabolism
in the brain (midbrain, striatum, hypothalamus, hippocampus etc.) likely for motor control and motivation in
sustaining exercise, but it was returned to resting levels at fatigue50?53. Furthermore, dopaminergic mechanism
could be involved in voluntary wheel running behavior in rodents31,40. These findings indicate the possibility for
the presence of a motivation, intrinsic motivation, for exercise/locomotion itself. In the present study, TTFD
increases locomotor activity via dopaminergic activation, independent of goals (Figs?1?4), suggesting a possible
role for TTFD to promote motivation for locomotion and exercise.
TTFD is a popular agent for countering physical fatigue. Long-term administration of TTFD ameliorates the
feeling of fatigue after exercise in trained participants24. Furthermore, six weeks of thiamine supplementation
increases appetite, happiness, and decreases fatigue in elderly people with marginal thiamine deficiency54. These
effects are likely exerted by TTFD/thiamine-derived TDP, a coenzyme of pyruvate dehydrogenase, which
supports glucose metabolism in skeletal muscles23. In addition, in the current study, we observed for the first time
that TTFD promotes dopamine release in the mPFC of normal healthy rats (Fig.?2D). Anti-depressant drugs,
such as the dopamine reuptake inhibitor bupuropion, increase brain dopamine levels, producing psychological
happiness in humans55 and preventing the onset of fatigue during prolonged exercise in rats56. Therefore, the
anti-fatigue effect of TTFD could be induced not only by a metabolic effect, but also by dopaminergic activation
in the brain.
Collectively, our findings provide direct evidence that TTFD administration induces voluntary locomotor
activity via D1-receptor-mediated dopaminergic activity in the mPFC. TTFD also induces voluntary running in
a dose-dependent manner, likely due to the same neural mechanism. This is the first study showing the effect of
TTFD on the central nervous system. TTFD might help to promote physical activity, thereby improving physical
and mental fitness.
Materials and Methods
Animals. Adult male Wister rats (SLC Inc., Shizuoka, Japan), housed and cared for in an animal facility, were
fed a standard pellet diet (MF, Oriental Yeast Co., Ltd, Tokyo, Japan) and given water ad libitum. The room
temperature was maintained at between 22 and 24 ?C under a 12 h light/dark cycle (lights on: 07:00?19:00). All
experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of
Tsukuba, and all procedures and methods were performed in accordance with the relevant guidelines laid down
by the animal ethics committee (Animal ethical approval number: 17-066). Every effort was made to minimize
the number of animals used as well as any pain and discomfort.
Measurement of amount of voluntary activity. As per the method described by Lynch et al.57, the
voluntary activity of rats was monitored in a cage (32 ? 20 ? 20 cm) using an Infrared Actimeter (Panlab, Barcelona,
Spain). This device is equipped with three transparent cages, each with eight infrared lights located in a frame
around the cage and connected to silent electronic counters. The apparatus is composed of a two-dimensional
(horizontal and vertical axes) square frame, a frame support and a control unit. The lower tier records horizontal
movements, while the upper tier records vertical movements. Samples were taken every 2 minutes. Raw data were
computed with Actitrack? software (Panlab, Barcelona, Spain). Rats were fully acclimatized to the device for
30 minutes per day for 1 week. On the day of the test, after confirming that the rats in the device cages had been
sedentary for 20 minutes, an i.p. injection of TTFD or a vehicle (saline) was administered. After administration,
rats were placed back into the device cages and their movements were monitored. Each movement produced a
signal caused by variation of inductance and capacity of the apparatus resonance circuit. These signals were
automatically converted into numbers and locomotion was counted by number of samples where the position of the
subject is different from its position during the previous sample and different to the position of the 2nd sample
back in time. This was separated from emotional activity without position movement. The activity of each rat was
automatically recorded for 120 minutes after TTFD administration.
Surgery for microdialysis in the mPFC. The rats were anesthetized with isoflurane and placed in a
stereotaxic instrument. An intracerebral guide cannula (outer diameter: 0.5 mm, AG-4, Eicom., Japan) was placed in the
prelimbic area of the mPFC projected by DNs from VTA to regulate motivated behaviors58,59 (3.7 mm anterior to the
bregma; 0.7 mm lateral; 3.0 mm below the pial surface)60. The cannula was secured to the skull with two anchoring
screws and dental cement. To prevent occlusion, a dummy cannula (AD-4, Eicom., Japan) was inserted into the
guide cannula. After the surgery, the animals were housed individually and were allowed to recover for at least week.
Microdialysis for dopamine detection in the mPFC. A microdialysis probe was inserted into the mPFC
via the implanted guide cannula connected and perfused with Ringer?s solution (147 mM NaCl, 4 mM KCl, and
2.3 mM CaCl2) at 2.0 ?l/min so as to allow freely moving condition. A stable dialysate dopamine and serotonin
concentration was usually obtained after a minimum of 2 h post-implantation of the probe. The 20?l of
microdialysate was collected in every 10 minutes using a fraction collector (EFC-82; Eicom, Japan), and then
automatically injected into an HPLC-ECD system (HTEC-500; Eicom, Japan) by an autosampler (M-510; Eicom, Japan).
Samples were analyzed for dopamine and serotonin concentration by the HPLC system with an EICOMPAK
CAX column (2.0 mm,i.d. ? 200 mm; Eicom, Japan) and a graft electrode (WE-3G; Eicom, Japan) set at 450 mV
(vs Ag/AgCl reference electrode)61. The mobile phase contained 0.1M ammonium acetate buffer, 0.05 mg/l
sodium sulfate, 50 mg/l EDTA, and methanol (7:3, v/v), with a pH of 6.0. For data analysis, basal dopamine and
serotonin concentration was estimated from an average of two HPLC time points before i.p. administration. At
the end of each experiment, rats euthanized with pentobarbital, and the brain was removed. The position of the
microdialysis probe was verified in coronal sections with Nissl staining.
Microdialysis for antagonism of dopamine receptors in the mPFC. The dosages of antagonists
used in this study were selected based on a previous study2. Rats were infused with a D1 antagonist (SCH23390;
10 mM) or a D2 antagonist (sulpiride; 10 mM) into the prelimbic area at a flow rate of 2 ?l/min via the
microdialysis probe. S-(?)-sulpiride was dissolved in 0.1 N acetic acid, then neutralized with 0.1 M NaHCO3 (pH 7.2)
and brought up to volume. Other antagonists were dissolved in artificial cerebral spinal fluid (aCSF, 145mM
NaCl, 2.7 mM KCl, 1 mM MgCl2, 1.2 mM CaCl2, and 0.1 mM ascorbic acid). Before and during antagonism, we
also collected dialysates, and these were analyzed for dopamine and serotonin concentrations using the HPLC
system with a PP-ODS II column (4.6 ? 30 mm; Eicom, Japan) and a graft electrode (WE-3G; Eicom, Japan) set
at 400 mV (vs Ag/AgCl reference electrode). The mobile phase contained 0.1M phosphate, 500 mg/l SDS, 50 mg/l
EDTA and 2% v/v methanol, with a pH of 5.462.
Measurement of voluntary running distance. As per the method described by Lee et al.41, the voluntary
running distance of rats was measured using a specially designed running-wheel apparatus (diameter = 31.8 cm,
width = 10 cm; Rat Analyzer KI-103, Aptec, Kyoto, Japan). The resistance necessary to overcome the inertia of the
wheel at its minimum load was 4.5 g. Distance is the number of revolutions times the circumference of the wheel.
Rats were housed individually and had free access to the running-wheel apparatus for 1 week to be acclimatized.
On the day of the experiment, the voluntary running distance of each rat was measured for 120 min.
Statistical analysis. Data are expressed as mean ? standard error and analyzed using prism 5 (MDF Co., Ltd,
Tokyo, Japan). Comparisons of the two groups were performed using Student?s t test for unpaired data. Group
comparisons were performed using a one-way ANOVA, or two-way ANOVA with post hoc tests, including the planned
comparisons38. Statistical significance was assumed at P < 0.05.
This work was supported in part by a joint research grant from Takeda Consumer Healthcare Company
Limited, special funds for Education and Research from the Ministry of Education, Culture, Sports, Science and
Technology (MEXT) granted to the ?Human High Performance (HHP) Research Project?, and Grant-in-Aid for
Scientific Research on Innovative Areas ?WILL DYNAMICS? (16H06405).
M. Saiki, T.M., M. Soya, S.N. and H.S. designed the study. M. Saiki, M. Soya, T.M., T.K. and T. Shima collected
the data. M. Saiki, T.M., M. Soya, T. Shimizu and H.S. performed the analysis. M. Saiki, T.M., M. Soya and H.S.
interpreted the data. M. Saiki, T.M., M. Soya, T.N., T.K., K.A., S.N. and H.S. wrote and revised the manuscript. All
authors have approved the submission of the final manuscript.
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-28462-2.
Competing Interests: The authors declare no competing interests. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article?s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article?s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
42. Vivar , C. & van Praag , H. Running Changes the Brain: the Long and the Short of It . Physiology (Bethesda) 32 , 410 - 424 ( 2017 ).
43. Suwabe , K. et al. Aerobic fitness associates with mnemonic discrimination as a mediator of physical activity effects: evidence for memory flexibility in young adults . Sci. Rep . 7 , 5140 ( 2017 ).
44. Hyodo , K. et al. The association between aerobic fitness and cognitive function in older men mediated by frontal lateralization . Neuroimage 125 , 291 - 300 ( 2016 ).
45. Erickson , K. I. et al. Exercise training increases size of hippocampus and improves memory . Proc. Natl. Acad. Sci. USA 108 , 3017 - 3022 ( 2011 ).
46. Hillman , C. H. , Erickson , K. I. & Kramer , A. F. Be smart, exercise your heart: exercise effects on brain and cognition . Nat. Rev. Neurosci. 9 , 58 - 65 ( 2008 ).
47. Robbins , T. W. & Everitt , B. J. Neurobehavioural mechanisms of reward and motivation . Curr. Opin. Neurobiol . 6 , 228 - 236 ( 1996 ).
48. Ferrario , C. R. et al. Homeostasis Meets Motivation in the Battle to Control Food Intake . J. Neurosci . 36 , 11469 - 11481 ( 2016 ).
49. Rogers , P. J. Food and drug addictions: Similarities and differences . Pharmacol. Biochem. Behav . 153 , 182 - 190 ( 2017 ).
50. McMorris , T. , Barwood , M. & Corbett , J. Central fatigue theory and endurance exercise: Toward an interoceptive model . Neurosci. Biobehav. Rev . in press ( 2018 ).
51. Bailey , S. P. , Davis , J. M. & Ahlborn , E. N. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue . J. Appl. Physiol . ( 1985 ) 74 , 3006 - 3012 ( 1993 ).
52. Heyes , M. P. , Garnett , E. S. & Coates , G. Nigrostriatal dopaminergic activity is increased during exhaustive exercise stress in rats . Life Sci . 42 , 1537 - 1542 ( 1988 ).
53. Goekint , M. et al. Acute running stimulates hippocampal dopaminergic neurotransmission in rats, but has no influence on brainderived neurotrophic factor . J. Appl. Physiol . ( 1985 ) 112 , 535 - 541 ( 2012 ).
54. Smidt , L. J. , Cremin , F. M. , Grivetti , L. E. & Clifford , A. J. Influence of thiamin supplementation on the health and general well-being of an elderly Irish population with marginal thiamin deficiency . J. Gerontol . 46 , M16 - 22 ( 1991 ).
55. Nutt , D. et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure . J. Psychopharmacol . 21 , 461 - 471 ( 2007 ).
56. Hasegawa , H. et al. Influence of brain catecholamines on the development of fatigue in exercising rats in the heat . J. Physiol . 586 , 141 - 149 ( 2008 ).
57. Lynch , J. J. 3rd , Castagne , V. , Moser , P. C. & Mittelstadt , S. W. Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies . J. Pharmacol. Toxicol. Methods 64 , 74 - 80 ( 2011 ).
58. Bjorklund , A. & Dunnett , S. B. Dopamine neuron systems in the brain: an update . Trends Neurosci . 30 , 194 - 202 ( 2007 ).
59. Peters , J. , Kalivas , P. W. & Quirk , G. J. Extinction circuits for fear and addiction overlap in prefrontal cortex . Learn. Mem . 16 , 279 - 288 ( 2009 ).
60. Gurden , H. , Takita , M. & Jay , T. M. Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo . J. Neurosci . 20 , RC106 ( 2000 ).
61. Yamamura , S. et al. Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex . Br. J. Pharmacol . 157 , 656 - 665 ( 2009 ).
62. Kobayashi , T. , Hayashi , E. , Shimamura , M. , Kinoshita , M. & Murphy , N. P. Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study . Psychopharmacology 197 , 567 - 580 ( 2008 ).